Nanna Therapeutics
Sarah Young is a Senior Project Scientist at Astellas Engineered Small Molecules U.K. Ltd. since February 2022, previously serving as a Scientist at Freeline from November 2020 to January 2022. Prior experience includes a role as a Postdoctoral Research Assistant at The Francis Crick Institute from September 2015 to November 2020, where Sarah also completed a PhD in Biochemistry at Imperial College London from 2015 to 2020. Earlier, Sarah was a Research Technician at The University of Edinburgh, where a Bachelor of Science in Molecular Genetics was earned from 2008 to 2012.
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer.Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treatage-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies.Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.